These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. A minor possibility of pharmacokinetic interaction between enoxacin and fenbufen in rats. Naora K; Katagiri Y; Ichikawa N; Hayashibara M; Iwamoto K J Pharmacobiodyn; 1990 Feb; 13(2):90-6. PubMed ID: 2384853 [TBL] [Abstract][Full Text] [Related]
43. Pharmacokinetics of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, in man. A study using a stable isotope techique. Heikkinen H; Saraheimo M; Antila S; Ottoila P; Pentikäinen PJ Eur J Clin Pharmacol; 2001; 56(11):821-6. PubMed ID: 11294372 [TBL] [Abstract][Full Text] [Related]
44. The effect of renal impairment and haemodialysis on single dose pharmacokinetics of oral enoxacin. Nix DE; Schultz RW; Frost RW; Sedman AJ; Thomas DJ; Kinkel AW; Schentag JJ J Antimicrob Chemother; 1988 Feb; 21 Suppl B():87-95. PubMed ID: 3162906 [TBL] [Abstract][Full Text] [Related]
45. Intravenous enoxacin for the treatment of acute pyelonephritis: pharmacokinetic and clinical study. Bailey RR; Walker RJ; Lynn KL; Donaldson IM; Peddie BA; Dobbs BR Br J Clin Pharmacol; 1988 Feb; 25(2):223-8. PubMed ID: 3162809 [TBL] [Abstract][Full Text] [Related]
46. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. Jansat JM; Costa J; Salvà P; Fernandez FJ; Martinez-Tobed A J Clin Pharmacol; 2002 Dec; 42(12):1303-10. PubMed ID: 12463724 [TBL] [Abstract][Full Text] [Related]
47. Effect of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide. Lahu G; Nassr N; Herzog R; Elmlinger M; Ruth P; Hinder M; Huennemeyer A J Clin Pharmacol; 2011 Apr; 51(4):586-93. PubMed ID: 20466871 [TBL] [Abstract][Full Text] [Related]
48. [The effectiveness of enoxacin for the treatment of complicated urinary tract infection]. Germinario C; Quarto M; Viggiani N; Schena FP Riv Eur Sci Med Farmacol; 1992; 14(5):347-51. PubMed ID: 1308966 [TBL] [Abstract][Full Text] [Related]
49. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Zhao JJ; Rogers JD; Holland SD; Larson P; Amin RD; Haesen R; Freeman A; Seiberling M; Merz M; Cheng H Biopharm Drug Dispos; 1997 Dec; 18(9):769-77. PubMed ID: 9429741 [TBL] [Abstract][Full Text] [Related]
50. Comparison of enoxacin versus trimethoprim-sulfamethoxazole in the treatment of patients with complicated urinary tract infection. Gottlieb PL Clin Ther; 1995; 17(3):493-502. PubMed ID: 7585853 [TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics of the quinolones in volunteers: a proposed dosing schedule. Wise R; Griggs D; Andrews JM Rev Infect Dis; 1988; 10 Suppl 1():S83-9. PubMed ID: 3162327 [TBL] [Abstract][Full Text] [Related]
53. Oral enoxacin versus conventional intravenous antimicrobial therapy for chronic osteomyelitis. Jauregui LE; Hageage G; Martin M J Chemother; 1989 Jul; 1(4 Suppl):735-6. PubMed ID: 16312614 [No Abstract] [Full Text] [Related]
54. The clinical pharmacokinetics and tolerance of enoxacin in healthy volunteers. Wolf R; Eberl R; Dunky A; Mertz N; Chang T; Goulet JR; Latts J J Antimicrob Chemother; 1984 Sep; 14 Suppl C():63-9. PubMed ID: 6389476 [TBL] [Abstract][Full Text] [Related]
55. The theophylline-enoxacin interaction: II. Changes in the disposition of theophylline and its metabolites during intermittent administration of enoxacin. Rogge MC; Solomon WR; Sedman AJ; Welling PG; Koup JR; Wagner JG Clin Pharmacol Ther; 1989 Oct; 46(4):420-8. PubMed ID: 2791445 [TBL] [Abstract][Full Text] [Related]
56. The absorption and disposition of enoxacin in healthy subjects. Somogyi AA; Bochner F J Clin Pharmacol; 1988 Aug; 28(8):707-13. PubMed ID: 3216037 [TBL] [Abstract][Full Text] [Related]
57. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing. Mueller BU; Anderson BD; Farley MQ; Murphy R; Zuckerman J; Jarosinski P; Godwin K; McCully CL; Mitsuya H; Pizzo PA; Balis FM Antimicrob Agents Chemother; 1998 Jul; 42(7):1815-8. PubMed ID: 9661027 [TBL] [Abstract][Full Text] [Related]
58. Pharmacokinetics of enoxacin and its penetration into bronchial secretions and lung tissue. Wijnands WJ; Vree TB; Baars AM; van Herwaarden CL J Antimicrob Chemother; 1988 Feb; 21 Suppl B():67-77. PubMed ID: 3162904 [TBL] [Abstract][Full Text] [Related]
59. Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever. Bethell DB; Day NP; Dung NM; McMullin C; Loan HT; Tam DT; Minh LT; Linh NT; Dung NQ; Vinh H; MacGowan AP; White LO; White NJ Antimicrob Agents Chemother; 1996 Sep; 40(9):2167-72. PubMed ID: 8878600 [TBL] [Abstract][Full Text] [Related]